Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Applications of Emerging Data in Resectable NSCLC
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.